# Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

> **NCT03794492** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 169 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Mycophenolate mofetil 500mg Tab. or 250mg Cap.
- **DRUG:** Tacrolimus
- **DRUG:** Methylprednisolone/prednisolone
- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT03794492
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-31
- **Primary completion:** 2022-07-22
- **Final completion:** 2023-04-27
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794492, "Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03794492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*